Humira Again Top-Selling Drug In U.S.
Title: Humira Again Top-Selling Drug In U.S.Category: Health NewsCreated: 10/4/2017 12:00:00 AMLast Editorial Review: 10/4/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - October 4, 2017 Category: Rheumatology Source Type: news

Humira Again Top-Selling Drug In U.S.
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 4, 2017 Category: General Medicine Source Type: news

Humira Again Top-Selling Drug In U.S.
Popular anti-inflammatory leads list of top-selling drugs for fifth straight year. (Source: WebMD Health)
Source: WebMD Health - October 3, 2017 Category: Consumer Health News Source Type: news

AbbVie, Amgen settlement sets Humira U.S. biosimilar launch for 2023
(Reuters) - Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen's cheaper biosimilar version of AbbVie's cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023, the companies said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - September 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie makes peace with Amgen over Humira patents
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 28, 2017 Category: Pharmaceuticals Source Type: news

AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Amgen
Agreements Provide Non-Exclusive License to Amgen for HUMIRA-Related Intellectual Property in the U.S. Effective Jan. 31, 2023, And in Other Markets on Different Dates Amgen Acknowledges Validity of AbbVie's Extensive Intellectual Property Portfolio for... Biopharmaceuticals, Generics, Litigation, Licensing AbbVie, Amgen, biosimilar, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 28, 2017 Category: Pharmaceuticals Source Type: news

Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA(TM)
Amgen to Begin Launching Biosimilar Adalimumab in Europe in 2018 THOUSAND OAKS, Calif., Sept. 28, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that it has reached a global settlement with AbbVie to resolve all ... Biopharmaceuticals, Generics, Litigation, Licensing Amgen, AbbVie, AMGEVITA, AMJEVITA, Humira, adalimumab, biosimilar (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 28, 2017 Category: Pharmaceuticals Source Type: news

Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA ™
Amgen to Begin Launching Biosimilar Adalimumab in Europe in 2018 THOUSAND OAKS, Calif., Sept. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has reached a global settlement with AbbVie to resolve all pending litigation regarding AMGEVITA™/AMJEVITA™, a biosimilar to AbbVie's Humira® (adalimumab). Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of AMGEVITA/AMJEVITA worldwide, on a country-by-country basis, and the companies have agreed to dismiss all pending litigation. Amgen expects to launch AMGEVITA in Europe on Oct. 16, 2018, and AMJEVITA in the Unit...
Source: Amgen News Release - September 28, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

RA Activity Stable After Prolonging Adalimumab Interval RA Activity Stable After Prolonging Adalimumab Interval
Reducing the frequency of adalimumab did not worsen disease activity or function in patients with rheumatoid arthritis and may safely lower treatment costs and risks for adverse events, a study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 27, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

RA Outcomes with Tocilizumab Surpass Those of Adalimumab, Methotrexate (CME/CE)
(MedPage Today) -- Benefits reflected in both physical and mental scores (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - September 25, 2017 Category: Rheumatology Source Type: news

Positive CHMP opinion for adalimumab biosimilar CYLTEZO
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 14, 2017 Category: Research Source Type: news

Cyltezo (Adalimumab-ADBM Injection, for Subcutaneous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 8, 2017 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira ®
Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: (Source: World Pharma News)
Source: World Pharma News - September 4, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira
Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a pre-filled syringe for the treatment of multiple... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 29, 2017 Category: Drugs & Pharmacology Source Type: news